Your browser doesn't support javascript.
loading
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
Weir, Ashley; Kang, Eun-Young; Meagher, Nicola S; Nelson, Gregg S; Ghatage, Prafull; Lee, Cheng-Han; Riggan, Marjorie J; Gentry-Maharaj, Aleksandra; Ryan, Andy; Singh, Naveena; Widschwendter, Martin; Alsop, Jennifer; Anglesio, Michael S; Beckmann, Matthias W; Berger, Jessica; Bisinotto, Christiani; Boros, Jessica; Brand, Alison H; Brenton, James D; Brooks-Wilson, Angela; Carney, Michael E; Cunningham, Julie M; Cushing-Haugen, Kara L; Cybulski, Cezary; Elishaev, Esther; Erber, Ramona; Fereday, Sian; Fischer, Anna; Paz-Ares, Luis; Gayarre, Javier; Gilks, Blake C; Grube, Marcel; Harnett, Paul R; Harris, Holly R; Hartmann, Arndt; Hein, Alexander; Hendley, Joy; Hernandez, Brenda Y; Heublein, Sabine; Huang, Yajue; Huzarski, Tomasz; Jakubowska, Anna; Jimenez-Linan, Mercedes; Kennedy, Catherine J; Kommoss, Felix K F; Koziak, Jennifer M; Kraemer, Bernhard; Le, Nhu D; Lesnock, Jaime; Lester, Jenny.
Afiliación
  • Weir A; School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, NSW, Australia.
  • Kang EY; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, NSW, Australia.
  • Meagher NS; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Nelson GS; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
  • Ghatage P; School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, NSW, Australia.
  • Lee CH; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, NSW, Australia.
  • Riggan MJ; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.
  • Gentry-Maharaj A; Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Ryan A; Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Singh N; Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.
  • Widschwendter M; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
  • Alsop J; MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Anglesio MS; MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Beckmann MW; Women's Cancer, Institute for Women's Health, University College London, London, UK.
  • Berger J; Department of Pathology, Barts Health National Health Service Trust, London, UK.
  • Bisinotto C; EUTOPS Institute, University of Innsbruck, Innsbruck, Austria.
  • Boros J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Brand AH; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
  • Brenton JD; British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, BC, Canada.
  • Brooks-Wilson A; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Carney ME; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Cunningham JM; Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Cushing-Haugen KL; Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia.
  • Cybulski C; Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia.
  • Elishaev E; The University of Sydney, Sydney, NSW, Australia.
  • Erber R; Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia.
  • Fereday S; The University of Sydney, Sydney, NSW, Australia.
  • Fischer A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Paz-Ares L; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
  • Gayarre J; Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
  • Gilks BC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Grube M; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Harnett PR; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  • Harris HR; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Hartmann A; Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Hein A; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Hendley J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Hernandez BY; Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
  • Heublein S; H12O-CNIO Lung Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Huang Y; Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Huzarski T; Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Jakubowska A; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Jimenez-Linan M; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
  • Kennedy CJ; The University of Sydney, Sydney, NSW, Australia.
  • Kommoss FKF; Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia.
  • Koziak JM; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Kraemer B; Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Le ND; Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Lesnock J; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Lester J; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Br J Cancer ; 128(1): 137-147, 2023 01.
Article en En | MEDLINE | ID: mdl-36323878
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article